GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

GAMMA Investing LLC lifted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 189.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,054 shares of the company’s stock after acquiring an additional 3,964 shares during the quarter. GAMMA Investing LLC’s holdings in Verve Therapeutics were worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp increased its position in Verve Therapeutics by 27.0% in the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after acquiring an additional 903,809 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Verve Therapeutics by 72.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock worth $7,547,000 after purchasing an additional 653,578 shares during the last quarter. Braidwell LP acquired a new stake in Verve Therapeutics in the third quarter valued at $3,020,000. Novo Holdings A S raised its position in Verve Therapeutics by 20.0% during the 2nd quarter. Novo Holdings A S now owns 2,400,000 shares of the company’s stock worth $11,712,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in Verve Therapeutics by 245.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 395,699 shares of the company’s stock worth $1,931,000 after buying an additional 281,173 shares during the period. Institutional investors own 97.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Royal Bank of Canada dropped their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group boosted their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright cut their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th.

Verve Therapeutics Stock Down 4.5 %

NASDAQ VERV opened at $5.25 on Wednesday. The firm has a market cap of $444.49 million, a P/E ratio of -2.13 and a beta of 1.68. The company’s 50 day moving average is $5.83 and its 200-day moving average is $5.74. Verve Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $6.87 million during the quarter, compared to analysts’ expectations of $2.75 million. During the same quarter in the previous year, the company earned ($0.72) earnings per share. Verve Therapeutics’s revenue for the quarter was up 120.2% on a year-over-year basis. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.